ITGAX and neoplasm: Of interest, in renal (Renca), colon (CT26) and prostate (TRAMP-C2) carcinoma models, Decitabine promoted MDSC differentiation into CD11c, MHC-II and CD86 competent antigen presenting cells, capable of protecting naïve mice from tumor challenge (102).